Bayer’s Legal Offensive and BASF’s €30 Billion Yardstick Reshape the Stock’s Narrative — But Can It Hold €50?

Bayer's stock doubles in a year as BASF's €20-30B agribusiness IPO sets valuation floor, Moody's upgrades outlook, Supreme Court win enables mass lawsuit dismissals, and CEO pursues structural overhaul via Ruveon LLC.

Bayer’s share price has more than doubled over the past twelve months, yet the rally’s latest leg owes as much to a competitor’s IPO plans as to a landmark court victory. The stock closed Friday at €50.18, within striking distance of its 52-week high, as investors weigh a cluster of structural and legal catalysts against technical warnings that have become hard to ignore.

BASF’s Agribusiness IPO Sets a Valuation Template

BASF is aiming to float its agricultural division in the second quarter of 2027, targeting a valuation of €20 billion to €30 billion, according to media reports. Bayer’s own crop-science unit, Crop Science, is significantly larger, and the implied multiples have prompted market participants to reassess the embedded value of Bayer’s separate segments. With Bayer’s total market capitalization standing at €49.24 billion, the BASF price tag provides a floor for how the market might eventually price the agri-business alone, reinforcing the view that the conglomerate’s parts are worth more than the whole.

Moody’s Upgrade and Apollo Cash Bolster the Balance Sheet

Rating agency Moody’s added to the positive momentum on July 12, lifting its outlook for Bayer from “stable” to “positive” while affirming the existing rating. The revision followed a court decision that reduces the risk of future legal liabilities, a key factor in the agency’s assessment. The improved credit profile aligns with Bayer’s ongoing efforts to strengthen its capital structure. Earlier this year, the company raised around €3.0 billion in equity by bringing in Apollo Global Management as a partner in its long-acting contraception business, with Bayer retaining operational control. The infusion has helped relieve balance-sheet pressure and gives the company more room to navigate its legal overhang.

Supreme Court Win Clears the Way for Mass Dismissals

Over the weekend, Bayer filed motions to dismiss roughly 4,000 bundled glyphosate lawsuits pending in U.S. federal courts. The legal foundation for those motions rests on a decisive Supreme Court ruling late last month in Monsanto v. Durnell. By a seven-to-two majority, the justices held that the federal pesticide labeling law, FIFRA, preempts state-law warning claims — meaning that because the EPA has repeatedly determined glyphosate is not carcinogenic and approved labels without cancer warnings, state-based failure-to-warn claims cannot stand.

Analysts see the dismissal push as a critical step toward restoring financial predictability for a company that has been weighed down by Monsanto-related litigation since the 2018 acquisition. If the strategy succeeds, a substantial portion of the remaining lawsuits could evaporate.

Ruveon LLC and the Break-Up Speculation

CEO Bill Anderson is pursuing a parallel structural overhaul. Bayer has already transferred its entire U.S. glyphosate business into a newly created subsidiary called Ruveon LLC, part of a five-year plan for the Crop Science division. Market observers interpret the divestment as an attempt to ring-fence legal risk and fuel speculation that a full split of the conglomerate is being prepared — speculation that has itself provided an extra tailwind for the share price in recent weeks.

The August 19 Court Date

Investors are now focused on a specific calendar event: on August 19, 2026, a U.S. court is scheduled to give final approval to the multibillion-dollar class-action settlement worth $7.25 billion. Should the court greenlight that deal and the current wave of dismissal motions also succeed, one of the most persistent uncertainties hanging over Bayer could be removed. Market participants are watching for any preliminary signals from federal judge Vincent Chhabria on whether the dismissal requests are likely to be granted, as a positive indication could move the stock well before the August hearing.

Technical Warning Signs Amid the Rally

The share price performance remains extraordinary by any measure. In the past month alone, Bayer has surged 39.16%, pushing year-to-date gains to 31.97% and the twelve-month advance to 81.75%. The stock now trades 33.18% above its 200-day moving average of €37.68, a powerful confirmation of the long-term uptrend. Yet the 14-day relative strength index stands at 70.4, a level that signals overbought conditions after such a rapid climb. The stock is also just 6.8% shy of its 52-week high of €53.86, which was reached on July 3.

Last week’s 1.41% decline suggests some cooling is under way, and the annualized volatility of 61.88% over the past 30 days reminds investors that Bayer remains highly sensitive to regulatory and legal news. The convergence of a clearer legal path, an industry valuation benchmark, an improved credit outlook, and fresh equity could provide a durable foundation for the shares. But the immediate test is whether the market can defend the €50 level after the breakneck pace of the past month — and whether the technical signals will force a pause before the August deadline arrives.